Steven A Stacker

List of Publications by Year
in descending order

134	14,156	22153	19749
papers	citations	59 h-index	117 g-index

136	136	136	12875
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pkd1 and Wnt5a genetically interact to control lymphatic vascular morphogenesis in mice. Developmental Dynamics, 2022, 251, 336-349.	1.8	3
2	Brain Vascular Microenvironments in Cancer Metastasis. Biomolecules, 2022, 12, 401.	4.0	7
3	Control of Gene Expression by Exosome-Derived Non-Coding RNAs in Cancer Angiogenesis and Lymphangiogenesis. Biomolecules, 2021, 11, 249.	4.0	15
4	Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy. Communications Biology, 2021, 4, 878.	4.4	6
5	RYK-mediated filopodial pathfinding facilitates midgut elongation. Development (Cambridge), 2020, 147, .	2.5	4
6	Soothing a Broken Heart. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1611-1613.	2.4	3
7	Evolutionary Differences in the Vegf/Vegfr Code Reveal Organotypic Roles for the Endothelial Cell Receptor Kdr in Developmental Lymphangiogenesis. Cell Reports, 2019, 28, 2023-2036.e4.	6.4	23
8	Non-canonical Wnt Signaling through Ryk Regulates the Generation of Somatostatin- and Parvalbumin-Expressing Cortical Interneurons. Neuron, 2019, 103, 853-864.e4.	8.1	31
9	CCL27/CCL28â€“CCR10 Chemokine Signaling Mediates Migration of Lymphatic Endothelial Cells. Cancer Research, 2019, 79, 1558-1572.	0.9	33
10	The Interplay Between Lymphatic Vessels and Chemokines. Frontiers in Immunology, 2019, 10, 518.	4.8	52
11	The evolving role of lymphatics in cancer metastasis. Current Opinion in Immunology, 2018, 53, 64-73.	5.5	88
12	The biochemistry, signalling and disease relevance of RYK and other WNT-binding receptor tyrosine kinases. Growth Factors, 2018, 36, 15-40.	1.7	42
13	Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis, 2018, 21, 425-532.	7.2	429
14	Deficiency of the Wnt receptor Ryk causes multiple cardiac and outflow tract defects. Growth Factors, 2018, 36, 58-68.	1.7	5
15	Emerging Roles for VEGF-D in Human Disease. Biomolecules, 2018, 8, 1.	4.0	125
16	Exit Stage Left: A Tumor Cellâ€™s Journey from Lymph Node to Beyond. Trends in Cancer, 2018, 4, 519-522.	7.4	7
17	A Three-Dimensional Lymphatic Endothelial Cell Tube Formation Assay to Identify Novel Kinases Involved in Lymphatic Vessel Remodeling. Assay and Drug Development Technologies, 2017, 15, 30-43.	1.2	6
18	Vegfd modulates both angiogenesis and lymphangiogenesis during zebrafish embryonic development. Development (Cambridge), 2017, 144, 507-518.	2.5	56

#	Article	IF	Citations
19	Systematic high-content genome-wide RNAi screens of endothelial cell migration and morphology. Scientific Data, 2017, 4, 170009.	5.3	23
20	Genome-wide functional analysis reveals central signaling regulators of lymphatic endothelial cell migration and remodeling. Science Signaling, 2017, 10, .	3.6	37
21	The fibrinolysis inhibitor Î±₂-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. Growth Factors, 2017, 35, 61-75.	1.7	6
22	Counting nuclei released from microcarrier-based cultures using pro-fluorescent nucleic acid stains and volumetric flow cytometry. BioTechniques, 2017, 63, 34-36.	1.8	4
23	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. Frontiers in Immunology, 2016, 7, 621.	4.8	132
24	Growth factors: the journey continues. Growth Factors, 2016, 34, 1-4.	1.7	3
25	VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury. Journal of Pathology, 2016, 239, 152-161.	4.5	24
26	Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D. Journal of Biological Chemistry, 2016, 291, 27265-27278.	3.4	35
27	Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nature Communications, 2016, 7, 10634.	12.8	232
28	A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors. Journal of Visualized Experiments, 2016, , .	0.3	10
29	The RYK Receptor Family. , 2015, , 685-741.		6
30	Expression and purification of bioactive, low-endotoxin recombinant human vitronectin. BioTechniques, 2014, 56, 331-3.	1.8	4
31	Wnt5a induces Ryk-dependent and -independent effects on callosal axon and dendrite growth. Growth Factors, 2014, 32, 11-17.	1.7	12
32	The Wnt Receptor Ryk Reduces Neuronal and Cell Survival Capacity by Repressing FOXO Activity During the Early Phases of Mutant Huntingtin Pathogenicity. PLoS Biology, 2014, 12, e1001895.	5.6	42
33	Ccbe1 regulates Vegfc-mediated induction of Vegfr3 signaling during embryonic lymphangiogenesis. Development (Cambridge), 2014, 141, 1239-1249.	2.5	145
34	Arap3 is dysregulated in a mouse model of hypotrichosisâ€“lymphedemaâ€“telangiectasia and regulates lymphatic vascular development. Human Molecular Genetics, 2014, 23, 1286-1297.	2.9	36
35	Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nature Reviews Cancer, 2014, 14, 159-172.	28.4	621
36	VEGFD regulates blood vascular development by modulating SOX18 activity. Blood, 2014, 123, 1102-1112.	1.4	65

#	Article	IF	Citations
37	Exploring the role of endothelium in the tumour response to anti-angiogenic therapy. Biochemical Society Transactions, 2014, 42, 1569-1575.	3.4	6
38	Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy. Molecular Therapy, 2014, 22, 18-27.	8.2	112
39	Ryk, a Receptor Regulating Wnt5a-Mediated Neurogenesis and Axon Morphogenesis of Ventral Midbrain Dopaminergic Neurons. Stem Cells and Development, 2013, 22, 2132-2144.	2.1	28
40	Lymphovascular and neural regulation of metastasis: Shared tumour signalling pathways and novel therapeutic approaches. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2013, 27, 409-425.	4.0	13
41	Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clinical and Experimental Metastasis, 2013, 30, 819-832.	3.3	37
42	Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis. Clinical and Experimental Metastasis, 2013, 30, 345-356.	3.3	26
43	Vascular Endothelial Growth Factor-d Modulates Caliber and Function of Initial Lymphatics in the Dermis. Journal of Investigative Dermatology, 2013, 133, 2074-2084.	0.7	36
44	The Propeptides of VEGF-D Determine Heparin Binding, Receptor Heterodimerization, and Effects on Tumor Biology. Journal of Biological Chemistry, 2013, 288, 8176-8186.	3.4	25
45	Where to now with the VEGF signalling pathway in cancer?. Chinese Journal of Cancer, 2013, 32, 297-302.	4.9	63
46	A Fully Human Inhibitory Monoclonal Antibody to the Wnt Receptor RYK. PLoS ONE, 2013, 8, e75447.	2.5	22
47	The Wnt Coreceptor Ryk Regulates Wnt/Planar Cell Polarity by Modulating the Degradation of the Core Planar Cell Polarity Component Vangl2. Journal of Biological Chemistry, 2012, 287, 44518-44525.	3.4	110
48	The Wnt Receptor Ryk Plays a Role in Mammalian Planar Cell Polarity Signaling. Journal of Biological Chemistry, 2012, 287, 29312-29323.	3.4	83
49	Towards the biomarker-guided rational use of antiangiogenic agents in the treatment of metastatic colorectal cancer. Colorectal Cancer, 2012, 1, 149-161.	0.8	7
50	Remodeling of the Lymphatic Vasculature during Mouse Mammary Gland Morphogenesis Is Mediated via Epithelial-Derived Lymphangiogenic Stimuli. American Journal of Pathology, 2012, 181, 2225-2238.	3.8	20
51	Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies. Protein Expression and Purification, 2012, 82, 232-239.	1.3	15
52	Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance. Growth Factors, 2012, 30, 283-296.	1.7	32
53	VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium. Cancer Cell, 2012, 21, 181-195.	16.8	244
54	Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 2012, 61, 702-710.	2.9	29

#	Article	IF	Citations
55	The connection between lymphangiogenic signalling and prostaglandin biology: A missing link in the metastatic pathway. Oncotarget, 2012, 3, 893-906.	1.8	47
56	The VD1 Neutralizing Antibody to Vascular Endothelial Growth Factor-D: Binding Epitope and Relationship to Receptor Binding. Journal of Molecular Biology, 2011, 407, 581-593.	4.2	15
57	Wnt5a Regulates Midbrain Dopaminergic Axon Growth and Guidance. PLoS ONE, 2011, 6, e18373.	2.5	86
58	A Role for Bone Morphogenetic Protein-4 in Lymph Node Vascular Remodeling and Primary Tumor Growth. Cancer Research, 2011, 71, 6547-6557.	0.9	59
59	Proteolytic processing of vascular endothelial growth factorâ€Ð is essential for its capacity to promote the growth and spread of cancer. FASEB Journal, 2011, 25, 2615-2625.	0.5	32
60	Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer. Reproductive Biology and Endocrinology, 2010, 8, 84.	3.3	13
61	Targeting lymphatic vessel functions through tyrosine kinases. Journal of Angiogenesis Research, 2010, 2, 13.	2.9	14
62	Genetic Dissection of Differential Signaling Threshold Requirements for the Wnt/Î²-Catenin Pathway In Vivo. PLoS Genetics, 2010, 6, e1000816.	3.5	81
63	Lymphangiogenesis in Cancer Metastasis. Cancer Metastasis - Biology and Treatment, 2009, , .	0.1	1
64	Lymphangiogenesis in Health and Disease â€“ An Overview. Cancer Metastasis - Biology and Treatment, 2009, , 1-9.	0.1	0
65	Molecular Control of Lymphatic Metastasis. Annals of the New York Academy of Sciences, 2008, 1131, 225-234.	3.8	229
66	Sox18 induces development of the lymphatic vasculature in mice. Nature, 2008, 456, 643-647.	27.8	483
67	From Anti-Angiogenesis to Anti-Lymphangiogenesis: Emerging Trends in Cancer Therapy. Lymphatic Research and Biology, 2008, 6, 165-172.	1.1	52
68	Importance of Wnt Signaling in the Tumor Stroma Microenvironment. Current Cancer Drug Targets, 2008, 8, 454-465.	1.6	39
69	Deletion of Vascular Endothelial Growth Factor C (VEGF-C) and VEGF-D Is Not Equivalent to VEGF Receptor 3 Deletion in Mouse Embryos. Molecular and Cellular Biology, 2008, 28, 4843-4850.	2.3	174
70	Editorial [Hot Topic:Targeting Tumor Stroma (Guest Editors: Marc G. Achen and Steven A. Stacker)]. Current Cancer Drug Targets, 2008, 8, 446-446.	1.6	5
71	Proprotein convertases promote processing of VEGFâ€Ð, a critical step for binding the angiogenic receptor VEGFRâ€². FASEB Journal, 2007, 21, 1088-1098.	0.5	100
72	Distinct Roles of Vascular Endothelial Growth Factor-D in Lymphangiogenesis and Metastasis. American Journal of Pathology, 2007, 170, 1348-1361.	3.8	119

#	Article	IF	Citations
73	A system for quantifying the patterning of the lymphatic vasculature. Growth Factors, 2007, 25, 417-425.	1.7	36
74	Lymphangiogenic Growth Factor Responsiveness Is Modulated by Postnatal Lymphatic Vessel Maturation. American Journal of Pathology, 2006, 169, 708-718.	3.8	125
75	Lymphatic endothelium: An important interactive surface for malignant cells. Pulmonary Pharmacology and Therapeutics, 2006, 19, 51-60.	2.6	30
76	Tumor lymphangiogenesis and metastatic spreadâ€"New players begin to emerge. International Journal of Cancer, 2006, 119, 1755-1760.	5.1	126
77	Lymphatic vessels in cancer metastasis: bridging the gaps. Carcinogenesis, 2006, 27, 1729-1738.	2.8	150
78	The Wnt Receptor Ryk Is Required for Wnt5a-Mediated Axon Guidance on the Contralateral Side of the Corpus Callosum. Journal of Neuroscience, 2006, 26, 5840-5848.	3.6	216
79	Targeting lymphangiogenesis to prevent tumour metastasis. British Journal of Cancer, 2006, 94, 1355-1360.	6.4	148
80	Molecular Pathways for Lymphangiogenesis and their Role in Human Disease. Novartis Foundation Symposium, 2006, 281, 38-49.	1.1	16
81	Focus on lymphangiogenesis in tumor metastasis. Cancer Cell, 2005, 7, 121-127.	16.8	291
82	Vascular Endothelial Growth Factor D Is Dispensable for Development of the Lymphatic System. Molecular and Cellular Biology, 2005, 25, 2441-2449.	2.3	232
83	Mechanisms of Lymphangiogenesis: Targets for Blocking the Metastatic Spread of Cancer. Current Cancer Drug Targets, 2005, 5, 561-571.	1.6	23
84	Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. Journal of Clinical Investigation, 2005, 115, 247-257.	8.2	475
85	Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. Journal of Clinical Investigation, 2005, 115, 247-257.	8.2	326
86	Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. International Journal of Oncology, 2005, 27, 669-79.	3.3	29
87	Expression of Vascular Endothelial Growth Factor Receptor-3 by Lymphatic Endothelial Cells Is Associated with Lymph Node Metastasis in Prostate Cancer. Clinical Cancer Research, 2004, 10, 5137-5144.	7.0	102
88	Adenoviral Catheter-Mediated Intramyocardial Gene Transfer Using the Mature Form of Vascular Endothelial Growth Factor-D Induces Transmural Angiogenesis in Porcine Heart. Circulation, 2004, 109, 1029-1035.	1.6	182
89	Molecular Targeting of Lymphatics for Therapy. Current Pharmaceutical Design, 2004, 10, 65-74.	1.9	37
90	Molecular regulation of the VEGF family Ã¢Â€Â“ inducers of angiogenesis and lymphangiogenesis. Apmis, 2004, 112, 463-480.	2.0	139

#	Article	IF	Citations
91	Lymphangiogenic growth factors as markers of tumor metastasis. Apmis, 2004, 112, 539-549.	2.0	64
92	Plasmin activates VEGF-C and VEGF-D. International Congress Series, 2004, 1262, 79-82.	0.2	1
93	VEGF receptors branch into new areas. Blood, 2004, 103, 4379-4380.	1.4	2
94	Pseudocowpox virus Encodes a Homolog of Vascular Endothelial Growth Factor. Virology, 2003, 305, 298-309.	2.4	44
95	EGFR blockade with ZD1839 (â€œIressaâ€) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics, 2003, 55, 713-723.	0.8	110
96	Angiogenic Responses of Vascular Endothelial Growth Factors in Periadventitial Tissue. Human Gene Therapy, 2003, 14, 1451-1462.	2.7	75
97	Regenerating lizard tails: A new model for investigating lymphangiogenesis. FASEB Journal, 2003, 17, 1-13.	0.5	27
98	Viral Vascular Endothelial Growth Factors Vary Extensively in Amino Acid Sequence, Receptor-binding Specificities, and the Ability to Induce Vascular Permeability yet Are Uniformly Active Mitogens. Journal of Biological Chemistry, 2003, 278, 38004-38014.	3.4	63
99	Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D. Journal of Experimental Medicine, 2003, 198, 863-868.	8.5	184
100	VEGF-D Is the Strongest Angiogenic and Lymphangiogenic Effector Among VEGFs Delivered Into Skeletal Muscle via Adenoviruses. Circulation Research, 2003, 92, 1098-1106.	4.5	374
101	Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovascular Research, 2003, 59, 971-979.	3.8	63
102	Vascular Endothelial Growth Factor D (VEGF-D). , 2003, , 559-564.		0
103	The role of tumor lymphangiogenesis in metastatic spread. FASEB Journal, 2002, 16, 922-934.	0.5	264
104	Adenovirus encoding vascular endothelial growth factorâ€“D induces tissue-specific vascular patterns in vivo. Blood, 2002, 99, 4434-4442.	1.4	102
105	The Angiogenic and Lymphangiogenic Factor Vascular Endothelial Growth Factor-D Exhibits a Paracrine Mode of Action in Cancer. Growth Factors, 2002, 20, 99-107.	1.7	54
106	Molecular control of lymphangiogenesis. BioEssays, 2002, 24, 1030-1040.	2.5	90
107	The vascular endothelial growth factor family; proteins which guide the development of the vasculature. International Journal of Experimental Pathology, 2002, 79, 255-265.	1.3	105
108	Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. Kidney International, 2002, 61, 1696-1706.	5.2	49

#	Article	IF	Citations
109	Lymphangiogenesis and cancer metastasis. Nature Reviews Cancer, 2002, 2, 573-583.	28.4	729
110	Inhibitors of Angiogenesis. , 2002, , 261-292.		0
111	VEGF-D is an X-linked/AP-1 Regulated Putative Onco-angiogen in Human Glioblastoma Multiforme. Molecular Medicine, 2001, 7, 598-608.	4.4	69
112	Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. Journal of Pathology, 2001, 193, 147-154.	4.5	130
113	Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO Journal, 2001, 20, 1223-1231.	7.8	583
114	VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nature Medicine, 2001, 7, 186-191.	30.7	1,113
115	The Specificity of Receptor Binding by Vascular Endothelial Growth Factor-D Is Different in Mouse and Man. Journal of Biological Chemistry, 2001, 276, 19166-19171.	3.4	152
116	Multiple Forms of Mouse Vascular Endothelial Growth Factor-D Are Generated by RNA Splicing and Proteolysis. Journal of Biological Chemistry, 2001, 276, 44307-44314.	3.4	59
117	Revelations of the RYK receptor. BioEssays, 2000, 23, 34-45.	2.5	36
118	Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. FEBS Journal, 2000, 267, 2505-2515.	0.2	101
119	Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk. Nature Genetics, 2000, 25, 414-418.	21.4	157
120	VEGFâ€C and VEGFâ€D expression in neuroendocrine cells and their receptor, VEGFRâ€3, in fenestrated blood vessels in human tissues. FASEB Journal, 2000, 14, 2087-2096.	0.5	299
121	Viral Vascular Endothelial Growth Factor Plays a Critical Role in Orf Virus Infection. Journal of Virology, 2000, 74, 10699-10706.	3.4	123
122	A Mutant Form of Vascular Endothelial Growth Factor (VEGF) That Lacks VEGF Receptor-2 Activation Retains the Ability to Induce Vascular Permeability. Journal of Biological Chemistry, 1999, 274, 34884-34892.	3.4	96
123	Biosynthesis of Vascular Endothelial Growth Factor-D Involves Proteolytic Processing Which Generates Non-covalent Homodimers. Journal of Biological Chemistry, 1999, 274, 32127-32136.	3.4	281
124	Genomic Structure and Expression of the Mouse Growth Factor Receptor Related to Tyrosine Kinases (Ryk). Journal of Biological Chemistry, 1999, 274, 7379-7390.	3.4	24
125	Mutagenesis and selection of PDZ domains that bind new protein targets. Nature Biotechnology, 1999, 17, 170-175.	17.5	84
126	The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development. Growth Factors, 1999, 17, 1-11.	1.7	52

#	Article	IF	Citations
127	Placenta Growth Factor and Vascular Endothelial Growth Factor are Co-Expressed During Early Embryonic Development. Growth Factors, 1997, 15, 69-80.	1.7	70
128	Tie2 Receptor Expression and Phosphorylation in Cultured Cells and Mouse Tissues. FEBS Journal, 1997, 244, 774-779.	0.2	35
129	Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell, 1995, 83, 301-311.	28.9	673
130	Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer. British Journal of Cancer, 1987, 56, 820-824.	6.4	39
131	A Serum Test for the Diagnosis and Monitoring the Progress of Breast Cancer. , 1987, , 217-227.		7
132	A New Breast Carcinoma Antigen Defined by a Monoclonal Antibody2. Journal of the National Cancer Institute, 1985, 75, 801-811.	6.3	61
133	The Lymphatics: On the Route to Cancer Metastasis. , 0, , 237-254.		0
134	Non-Canonical Wnt-Signaling through Ryk Regulates the Generation of Somatostatin- and Parvalbumin-Expressing Cortical Interneurons. SSRN Electronic Journal, 0, , .	0.4	0